Mouse and human FcRs have been a major focus of attention not only of the scientific
community, through the cloning and characterization of novel receptors, and of the medical …

The discovery of both cytotoxic T lymphocyte-associated antigen 4 (CTLA4) and
programmed cell death protein 1 (PD1) as negative regulators of antitumour immunity led to …

Immune cell populations in the skin are predominantly comprised of dendritic cells (DCs)
and macrophages. A lack of consensus regarding how to define these cell types has …

The use of monoclonal antibodies (mAbs) as therapeutic tools has increased dramatically in
the last decade and is now one of the mainstream strategies to treat cancer. Nonetheless, it …

CD20 is a cell-surface marker expressed on mature B cells and most malignant B cells, but
not stem or plasma cells. It is an ideal target for monoclonal antibodies (mAb), such as …

Cancer metastasis is the leading cause of cancer-related death. Circulating tumor cells
(CTCs) are shed into the bloodstream from either primary or metastatic tumors during an …

Abstract Development of human therapeutic Abs has led to reduced immunogenicity and
optimal interactions with the human immune system in patients. Humanization had as a …

ABSTRACT Immunotherapy of cancer has been explored for over a century, but it is only in
the last decade that various antibody‐based products have been introduced into the …

Since the first report of the successful use of a monoclonal antibody for the treatment of
human B cell lymphoma in 1982, several antibodies have become incorporated into …

Fc gamma receptor I (FcγRI) contributes to protective immunity against bacterial infections,
but exacerbates certain autoimmune diseases. The sole high-affinity IgG receptor, FcγRI …